Our Trials

Clinical Trials for VAL-083

VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

Requests for Expanded Access

This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Kintara Therapeutics, Inc. will follow when considering requests by licensed physicians for use of Kintara’s investigational drugs outside of clinical trials.

View Policy


For more information on enrollment into the current VAL-083 trial, please contact us or visit clinicaltrials.gov for location information.

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.